Free Trial
OTCMKTS:BNXTF

BioNxt Solutions Q2 2026 Earnings Report

BioNxt Solutions logo
$0.27 0.00 (0.00%)
As of 10/2/2026

BioNxt Solutions EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BioNxt Solutions Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioNxt Solutions Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BioNxt Solutions Earnings Headlines

Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
BioNxt Solutions Inc.
See More BioNxt Solutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioNxt Solutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNxt Solutions and other key companies, straight to your email.

About BioNxt Solutions

BioNxt Solutions (OTCMKTS:BNXTF) is a biotechnology company focused on developing pharmaceutical and drug-delivery technologies. Its work centers on alternative dosage forms designed to improve the administration, absorption, and convenience of medicines, including oral dissolvable and sublingual films, transdermal systems, and other novel delivery platforms.

The company’s development activities have included pharmaceutical products and delivery systems targeting areas such as neurological disorders and other medical conditions. BioNxt has also pursued the development and commercialization of proprietary formulations and related technologies through partnerships and operating activities in North America and Europe, including Germany.

BioNxt Solutions was formerly known as XPhyto Therapeutics Corp. and adopted its current name as it focused more directly on pharmaceutical development and drug-delivery solutions. The company is headquartered in Vancouver, British Columbia, and its leadership has included Chief Executive Officer Hugh Rogers.

View BioNxt Solutions Profile